Biogen Idec (NQ:BIIB)

Discover which S&P500 stocks are making waves on Monday. ↗

October 12, 2026

Via Chartmill

Performance

52-Week Range 3.1% below 52-week high

233.53

138.0052W Low 240.9952W High

1 Week 3.1% below 1-week high

219.221W Low 240.991W High

Biogen Idec (BIIB) traded between $138.00 and $240.99 over the past 52 weeks and last traded at $233.53, 3.1% below its 52-week high. Over the past week it ranged between $219.22 and $240.99.

Past 12 Months

+3.5%

+8.0%

+11.8%

+32.7%

+31.3%

+62.6%

1W +$7.82

1M +$17.37

3M +$24.62

6M +$57.51

YTD +$55.72

1Y +$89.88

BIIB was +62.6% over the past year, +32.7% over six months, +31.3% year to date, +3.5% in the last week.

12 Months vs Market

BIIB

+62.6%

DIA

+13.4%

SPY

+16.0%

QQQ

+19.7%

IWM

+9.9%

Over the past 12 months BIIB returned +62.6% versus DIA (Dow) +13.4%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +19.7% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 0.08× 3-mo avg

Today 84,788 3-mo avg 1.0M

1.4M

1.2M

1.0M

1.1M

YTD

1.2M

1.4M

BIIB most recently traded 84,788 shares against a 3-month average daily volume of 1.0M.

More News

Biogen (BIIB) Stock Is Up, What You Need To Know

October 12, 2026

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

October 12, 2026

Via Chartmill

2 Surging Stocks for Long-Term Investors and 1 We Brush Off

October 12, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

October 07, 2026

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

October 02, 2026

From Biogen Inc.

1 Profitable Stock Worth Investigating and 2 We Ignore

October 01, 2026

Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

September 30, 2026

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

September 24, 2026

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

September 23, 2026

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

September 17, 2026

From Biogen Inc.

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗

September 15, 2026

Via MarketBeat

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗

September 12, 2026

Via MarketBeat

Thursday's session: top gainers and losers in the S&P500 index ↗

September 10, 2026

Via Chartmill

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)

September 07, 2026

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

September 03, 2026

From Biogen Inc.